/** * 新兴治疗技术框架 (Emerging Therapeutics Framework) * * ███████╗███╗ ███╗███████╗██████╗ ██████╗ ██╗███╗ ██╗ ██████╗ * ██╔════╝████╗ ████║██╔════╝██╔══██╗██╔════╝ ██║████╗ ██║██╔════╝ * █████╗ ██╔████╔██║█████╗ ██████╔╝██║ ███╗██║██╔██╗ ██║██║ ███╗ * ██╔══╝ ██║╚██╔╝██║██╔══╝ ██╔══██╗██║ ██║██║██║╚██╗██║██║ ██║ * ███████╗██║ ╚═╝ ██║███████╗██║ ██║╚██████╔╝██║██║ ╚████║╚██████╔╝ * ╚══════╝╚═╝ ╚═╝╚══════╝╚═╝ ╚═╝ ╚═════╝ ╚═╝╚═╝ ╚═══╝ ╚═════╝ * * Cutting-edge cancer treatment technologies and novel targets: * - 细胞治疗 (Cellular Therapies) * - 靶向蛋白降解 (Targeted Protein Degradation) * - 基因编辑 (Gene Editing) * - 新型抗体技术 (Novel Antibody Technologies) * - 纳米医学 (Nanomedicine) * - 人工智能药物发现 (AI-Driven Drug Discovery) */ // ═══════════════════════════════════════════════════════════════════════════════ // INTERFACES // ═══════════════════════════════════════════════════════════════════════════════ export interface EmergingTherapy { id: string; name: string; category: 'cellular' | 'small_molecule' | 'antibody' | 'nucleic_acid' | 'gene_therapy' | 'radiation' | 'other'; mechanism: string; targets: string[]; cancerTypes: string[]; developmentStage: 'preclinical' | 'phase_1' | 'phase_2' | 'phase_3' | 'approved' | 'breakthrough_therapy'; keyTrials: string[]; advantages: string[]; challenges: string[]; estimatedTimeline: string; companies: string[]; references: string[]; } export interface NovelTarget { gene: string; protein: string; pathway: string; targetType: 'oncogene' | 'tumor_suppressor' | 'synthetic_lethality' | 'immune' | 'metabolic' | 'epigenetic' | 'other'; druggability: 'high' | 'medium' | 'low' | 'undruggable_becoming_druggable'; cancerTypes: string[]; approachesInDevelopment: string[]; leadCompounds: { name: string; stage: string; company: string }[]; rationale: string; references: string[]; } export interface NextGenCellularTherapy { id: string; name: string; type: 'car_t' | 'car_nk' | 'til' | 'tcr_t' | 'car_m' | 'ipsc_derived' | 'gamma_delta' | 'nkt'; target: string; generation: string; modifications: string[]; cancerTypes: string[]; advantages: string[]; clinicalStatus: string; keyTrials: string[]; manufacturers: string[]; } export interface ProteinDegrader { id: string; name: string; type: 'protac' | 'molecular_glue' | 'lysosome_targeting' | 'autophagy'; target: string; e3Ligase: string; linker: string; cancerTypes: string[]; status: string; advantages: string[]; company: string; references: string[]; } export interface RadiopharmaceuticalTherapy { id: string; name: string; radioisotope: string; halfLife: string; emissionType: 'beta' | 'alpha' | 'auger'; targetingMoiety: string; target: string; cancerTypes: string[]; approvalStatus: string; keyTrials: string[]; advantages: string[]; sideEffects: string[]; } export interface AIDiscoveredDrug { id: string; name: string; aiPlatform: string; discoveryMethod: string; target: string; indication: string; developmentStage: string; company: string; timeFromDiscoveryToClinic: string; novelty: string; } // ═══════════════════════════════════════════════════════════════════════════════ // EMERGING THERAPEUTICS MODULE // ═══════════════════════════════════════════════════════════════════════════════ export class EmergingTherapeuticsModule { // ═══════════════════════════════════════════════════════════════════════════════ // NEXT-GENERATION CELLULAR THERAPIES // ═══════════════════════════════════════════════════════════════════════════════ private nextGenCellular: NextGenCellularTherapy[] = [ // NEXT-GEN CAR-T { id: 'cell-cart-armored', name: 'Armored CAR-T Cells', type: 'car_t', target: 'Various', generation: '4th Generation', modifications: ['Constitutive IL-15 secretion', 'IL-21 secretion', 'PD-1 dominant negative', '4-1BBL co-stimulation', 'Checkpoint knockout'], cancerTypes: ['Solid Tumors', 'Hematologic Malignancies'], advantages: ['Enhanced persistence', 'TME modulation', 'Reduced exhaustion', 'Better solid tumor activity'], clinicalStatus: 'Phase I/II trials', keyTrials: ['Multiple ongoing trials'], manufacturers: ['Lyell Immunopharma', 'Poseida', 'Caribou'] }, { id: 'cell-cart-allogeneic', name: 'Allogeneic Off-the-Shelf CAR-T', type: 'car_t', target: 'CD19, BCMA, CD70', generation: 'Allogeneic', modifications: ['TCR knockout (TRAC)', 'HLA knockout', 'CD52 knockout for lymphodepletion resistance', 'NK cell evasion'], cancerTypes: ['B-cell malignancies', 'Multiple Myeloma', 'T-cell malignancies'], advantages: ['Immediate availability', 'Lower cost potential', 'Standardized product', 'No apheresis needed'], clinicalStatus: 'Phase I/II - Mixed results, improving', keyTrials: ['ALPHA2', 'COBALT-LYM', 'UNIVERSAL'], manufacturers: ['Allogene', 'CRISPR Therapeutics', 'Precision BioSciences', 'Caribou Biosciences'] }, { id: 'cell-cart-logic-gated', name: 'Logic-Gated CAR-T', type: 'car_t', target: 'Multiple antigens', generation: 'Synthetic Biology', modifications: ['AND gate (require 2 antigens)', 'NOT gate (avoid normal tissues)', 'OR gate (target either)', 'SynNotch receptors'], cancerTypes: ['Solid tumors with heterogeneous expression'], advantages: ['Improved specificity', 'Reduced on-target off-tumor toxicity', 'Adaptable'], clinicalStatus: 'Phase I trials', keyTrials: ['Emerging'], manufacturers: ['A2 Biotherapeutics', 'Poseida', 'Tmunity'] }, { id: 'cell-cart-in-vivo', name: 'In Vivo CAR-T Generation', type: 'car_t', target: 'CD19', generation: 'In Vivo Programming', modifications: ['LNP-delivered mRNA', 'No ex vivo manufacturing', 'Repeated dosing possible'], cancerTypes: ['B-cell malignancies'], advantages: ['No manufacturing delay', 'Lower cost', 'Outpatient potential', 'Repeat dosing'], clinicalStatus: 'Phase I', keyTrials: ['LUMNI-T'], manufacturers: ['Capstan Therapeutics', 'Ensoma', 'Umoja Biopharma'] }, // CAR-NK { id: 'cell-car-nk', name: 'CAR-NK Cells', type: 'car_nk', target: 'CD19, CD70, HER2, NKG2D ligands', generation: 'Various', modifications: ['Cord blood derived', 'iPSC-derived', 'IL-15 armored', 'CD16 enhanced (ADCC)'], cancerTypes: ['Hematologic malignancies', 'Solid tumors'], advantages: ['No GvHD', 'Off-the-shelf potential', 'No CRS', 'Native anti-tumor activity'], clinicalStatus: 'Phase I/II', keyTrials: ['NCT03056339 (MD Anderson)', 'THINK trial'], manufacturers: ['Fate Therapeutics', 'Nkarta', 'Century Therapeutics', 'Takeda'] }, // TIL THERAPY { id: 'cell-til', name: 'Tumor-Infiltrating Lymphocyte (TIL) Therapy', type: 'til', target: 'Tumor neoantigens', generation: 'Autologous', modifications: ['Lifileucel (FDA approved)', 'Selected TIL', 'Gene-edited TIL', 'Neoantigen-enriched'], cancerTypes: ['Melanoma (approved)', 'NSCLC', 'Cervical', 'Head and Neck', 'Other solid tumors'], advantages: ['Polyclonal response', 'Target multiple neoantigens', 'Proven efficacy in melanoma'], clinicalStatus: 'FDA Approved (Melanoma), Phase II/III (other)', keyTrials: ['C-144-01', 'IOV-COM-202'], manufacturers: ['Iovance Biotherapeutics', 'Instil Bio', 'BioNTech'] }, // TCR-T { id: 'cell-tcr-t', name: 'TCR-T Cell Therapy', type: 'tcr_t', target: 'Intracellular antigens (MAGE-A4, NY-ESO-1, WT1, KRAS)', generation: 'Engineered TCR', modifications: ['Affinity-enhanced TCR', 'HLA-independent TCR mimic', 'Soluble TCR bispecifics'], cancerTypes: ['Synovial sarcoma', 'Myxoid liposarcoma', 'Melanoma', 'NSCLC', 'Ovarian'], advantages: ['Target intracellular antigens', 'Broader target space', 'Shared tumor antigens'], clinicalStatus: 'Phase I/II - Afami-cel approved', keyTrials: ['SPEARHEAD-1', 'IGNYTE-ESO'], manufacturers: ['Adaptimmune', 'TCR2', 'Immatics'] }, // IPSC-DERIVED { id: 'cell-ipsc', name: 'iPSC-Derived Cellular Therapies', type: 'ipsc_derived', target: 'Various', generation: 'iPSC Platform', modifications: ['Unlimited expansion', 'Genetic engineering', 'NK cells, T cells, macrophages'], cancerTypes: ['Hematologic and solid tumors'], advantages: ['Unlimited supply', 'Consistent quality', 'Multi-edit capability', 'Off-the-shelf'], clinicalStatus: 'Phase I', keyTrials: ['FT500 series', 'FT819 (CD19 CAR)'], manufacturers: ['Fate Therapeutics', 'Century Therapeutics', 'Shoreline Biosciences'] }, // GAMMA-DELTA T CELLS { id: 'cell-gamma-delta', name: 'Gamma-Delta T Cell Therapy', type: 'gamma_delta', target: 'Stress ligands, BTN3A1', generation: 'Vγ9Vδ2', modifications: ['Ex vivo expanded', 'CAR-modified', 'Allogeneic'], cancerTypes: ['Hematologic malignancies', 'Solid tumors'], advantages: ['MHC-unrestricted', 'Recognize stressed cells', 'Allogeneic safe', 'Tissue resident'], clinicalStatus: 'Phase I/II', keyTrials: ['Multiple ongoing'], manufacturers: ['IN8bio', 'Adicet Bio', 'Lava Therapeutics'] }, // CAR-MACROPHAGES { id: 'cell-car-m', name: 'CAR-Macrophage Therapy', type: 'car_m', target: 'HER2, Mesothelin', generation: '1st Generation', modifications: ['Chimeric antigen receptor on macrophages', 'Phagocytosis and antigen presentation'], cancerTypes: ['Solid tumors (HER2+, Mesothelin+)'], advantages: ['Solid tumor trafficking', 'TME remodeling', 'Antigen presentation', 'No CRS expected'], clinicalStatus: 'Phase I', keyTrials: ['CT-0508'], manufacturers: ['Carisma Therapeutics', 'Myeloid Therapeutics'] }, ]; // ═══════════════════════════════════════════════════════════════════════════════ // TARGETED PROTEIN DEGRADERS (PROTACS, MOLECULAR GLUES) // ═══════════════════════════════════════════════════════════════════════════════ private proteinDegraders: ProteinDegrader[] = [ { id: 'protac-ar', name: 'AR-PROTAC (Bavdegalutamide/ARV-110)', type: 'protac', target: 'Androgen Receptor', e3Ligase: 'Cereblon', linker: 'PEG-based', cancerTypes: ['Metastatic Castration-Resistant Prostate Cancer'], status: 'Phase II', advantages: ['Degrades full-length and variants', 'Overcomes AR mutations', 'Oral bioavailable'], company: 'Arvinas', references: ['ASCO 2023'] }, { id: 'protac-er', name: 'ER-PROTAC (Vepdegestrant/ARV-471)', type: 'protac', target: 'Estrogen Receptor', e3Ligase: 'Cereblon', linker: 'Optimized', cancerTypes: ['ER+ Breast Cancer', 'ESR1 mutant'], status: 'Phase III (VERITAC)', advantages: ['Degrades ER including ESR1 mutants', 'Oral SERD replacement', 'Combination with CDK4/6i'], company: 'Arvinas/Pfizer', references: ['SABCS 2023', 'VERITAC-2'] }, { id: 'protac-bcl-xl', name: 'BCL-XL PROTAC (DT2216)', type: 'protac', target: 'BCL-XL', e3Ligase: 'VHL', linker: 'Optimized', cancerTypes: ['T-cell lymphoma', 'AML', 'Solid tumors'], status: 'Phase I', advantages: ['Platelet-sparing degradation', 'Selective toxicity'], company: 'Dialectic Therapeutics', references: ['Preclinical publications'] }, { id: 'protac-brd4', name: 'BRD4-PROTAC (FHD-609)', type: 'protac', target: 'BRD4', e3Ligase: 'Cereblon', linker: 'Click chemistry', cancerTypes: ['Synovial sarcoma', 'AML'], status: 'Phase I', advantages: ['Deep BRD4 degradation', 'Overcomes BET inhibitor resistance'], company: 'Foghorn Therapeutics', references: ['Ongoing trials'] }, { id: 'protac-stat3', name: 'STAT3-PROTAC (KT-333)', type: 'protac', target: 'STAT3', e3Ligase: 'Cereblon', linker: 'Optimized', cancerTypes: ['Liquid and solid tumors with STAT3 activation'], status: 'Phase I', advantages: ['Degrades "undruggable" STAT3', 'Pan-tumor potential'], company: 'Kymera Therapeutics', references: ['ASCO 2023'] }, { id: 'protac-irak4', name: 'IRAK4-PROTAC (KT-474)', type: 'protac', target: 'IRAK4', e3Ligase: 'Cereblon', linker: 'Optimized', cancerTypes: ['MYD88-mutant DLBCL', 'Inflammatory conditions'], status: 'Phase II', advantages: ['Blocks TLR/IL-1R signaling', 'MYD88 mutation specific'], company: 'Kymera/Sanofi', references: ['Phase I data 2023'] }, { id: 'glue-gspt1', name: 'GSPT1 Molecular Glue (MRT-2359)', type: 'molecular_glue', target: 'GSPT1 (Translation termination)', e3Ligase: 'Cereblon', linker: 'N/A (direct)', cancerTypes: ['MYC-driven cancers', 'SCLC', 'Multiple myeloma'], status: 'Phase I', advantages: ['Novel MOA - translation termination', 'MYC vulnerability'], company: 'Monte Rosa Therapeutics', references: ['Cell 2022'] }, { id: 'glue-ikzf2', name: 'IKZF2 (Helios) Degrader (Mezigdomide)', type: 'molecular_glue', target: 'IKZF2/Aiolos/Ikaros', e3Ligase: 'Cereblon', linker: 'N/A', cancerTypes: ['Multiple Myeloma', 'DLBCL'], status: 'Phase III (SUCCESSOR-1)', advantages: ['More potent than lenalidomide', 'Overcomes IMiD resistance'], company: 'BMS', references: ['ASH 2023'] }, { id: 'glue-cdk-cyclin', name: 'CDK/Cyclin Molecular Glue', type: 'molecular_glue', target: 'CDK2/Cyclin E', e3Ligase: 'DDB1-CUL4', linker: 'N/A', cancerTypes: ['CDK4/6i resistant breast cancer', 'RB-deficient tumors'], status: 'Preclinical/Phase I', advantages: ['Overcomes CDK4/6i resistance', 'Cyclin E amplification'], company: 'Multiple', references: ['Nature 2023'] }, ]; // ═══════════════════════════════════════════════════════════════════════════════ // RADIOPHARMACEUTICALS (ALPHA, BETA, AUGER EMITTERS) // ═══════════════════════════════════════════════════════════════════════════════ private radiopharmaceuticals: RadiopharmaceuticalTherapy[] = [ { id: 'rp-psma-617', name: 'Lu-177 PSMA-617 (Pluvicto)', radioisotope: 'Lutetium-177', halfLife: '6.7 days', emissionType: 'beta', targetingMoiety: 'Small molecule PSMA ligand', target: 'PSMA', cancerTypes: ['Metastatic Castration-Resistant Prostate Cancer'], approvalStatus: 'FDA Approved', keyTrials: ['VISION', 'PSMAfore'], advantages: ['Targeted internal radiation', 'Imaging-therapy theranostic', 'Good tolerability'], sideEffects: ['Dry mouth', 'Fatigue', 'Cytopenias', 'Renal (rare)'] }, { id: 'rp-dotatate', name: 'Lu-177 DOTATATE (Lutathera)', radioisotope: 'Lutetium-177', halfLife: '6.7 days', emissionType: 'beta', targetingMoiety: 'Somatostatin analogue', target: 'SSTR2', cancerTypes: ['GI NETs', 'Pancreatic NETs', 'Paraganglioma/Pheochromocytoma'], approvalStatus: 'FDA Approved', keyTrials: ['NETTER-1', 'NETTER-2'], advantages: ['PRRT standard of care', 'Good response rates', 'Theranostic with Ga-68'], sideEffects: ['Nausea', 'Fatigue', 'Cytopenias', 'Carcinoid crisis (prevention needed)'] }, { id: 'rp-actinium-psma', name: 'Actinium-225 PSMA (Ac-225 PSMA)', radioisotope: 'Actinium-225', halfLife: '10 days', emissionType: 'alpha', targetingMoiety: 'PSMA ligand', target: 'PSMA', cancerTypes: ['mCRPC (Lu-177 refractory)'], approvalStatus: 'Investigational', keyTrials: ['AcTION', 'Various institutional'], advantages: ['Alpha particles - high LET', 'Overcomes Lu-177 resistance', 'DNA double-strand breaks'], sideEffects: ['Xerostomia (significant)', 'Renal toxicity concerns', 'Daughter isotope redistribution'] }, { id: 'rp-fapi', name: 'Lu-177/Ac-225 FAPI', radioisotope: 'Lutetium-177 or Actinium-225', halfLife: 'Variable', emissionType: 'beta', targetingMoiety: 'Fibroblast Activation Protein Inhibitor', target: 'FAP (tumor stroma)', cancerTypes: ['Pan-solid tumors', 'Pancreatic', 'Colorectal', 'Sarcoma'], approvalStatus: 'Investigational', keyTrials: ['Multiple Phase I/II'], advantages: ['Broad tumor targeting', 'Stromal targeting', 'Theranostic'], sideEffects: ['Under investigation'] }, { id: 'rp-pb212', name: 'Pb-212 DOTAMTATE', radioisotope: 'Lead-212', halfLife: '10.6 hours', emissionType: 'alpha', targetingMoiety: 'Somatostatin analogue', target: 'SSTR2', cancerTypes: ['Neuroendocrine tumors'], approvalStatus: 'Phase II/III (TREASURE)', keyTrials: ['TREASURE'], advantages: ['Alpha particle therapy', 'Shorter half-life (less lodging)', 'AlphaMedix platform'], sideEffects: ['Under investigation'] }, { id: 'rp-her2-adc-rad', name: 'Radiolabeled HER2 ADC', radioisotope: 'Various', halfLife: 'Variable', emissionType: 'beta', targetingMoiety: 'Antibody-drug conjugate', target: 'HER2', cancerTypes: ['HER2+ Breast', 'HER2+ Gastric'], approvalStatus: 'Investigational', keyTrials: ['Emerging'], advantages: ['Combines ADC with radioimmunotherapy', 'Bystander effect'], sideEffects: ['Under investigation'] }, { id: 'rp-i131-mibg', name: 'I-131 MIBG (Azedra)', radioisotope: 'Iodine-131', halfLife: '8 days', emissionType: 'beta', targetingMoiety: 'Norepinephrine analogue', target: 'Norepinephrine transporter', cancerTypes: ['Pheochromocytoma', 'Paraganglioma', 'Neuroblastoma'], approvalStatus: 'FDA Approved', keyTrials: ['Pivotal trials completed'], advantages: ['Theranostic with imaging', 'Established efficacy'], sideEffects: ['Myelosuppression', 'Thyroid protection needed'] }, ]; // ═══════════════════════════════════════════════════════════════════════════════ // NOVEL ANTIBODY TECHNOLOGIES // ═══════════════════════════════════════════════════════════════════════════════ private novelAntibodyTech: EmergingTherapy[] = [ { id: 'ab-trispecific', name: 'Trispecific Antibodies', category: 'antibody', mechanism: 'Engage T-cells + NK-cells + tumor antigen simultaneously', targets: ['HER2xCD3xCD16', 'BCMAxCD3xCD28', 'Other combinations'], cancerTypes: ['Solid tumors', 'Hematologic malignancies'], developmentStage: 'phase_1', keyTrials: ['Multiple early phase'], advantages: ['Multi-mechanism killing', 'Enhanced ADCC + T-cell engagement', 'Costimulation built-in'], challenges: ['Manufacturing complexity', 'Potential for enhanced toxicity'], estimatedTimeline: '3-5 years to approval', companies: ['Sanofi', 'Genentech', 'Xencor'], references: ['Early clinical data 2023'] }, { id: 'ab-probody', name: 'Probody (Masked Antibodies)', category: 'antibody', mechanism: 'Masked in normal tissue, activated in TME by proteases', targets: ['CD166', 'CD71', 'PD-L1', 'CD47'], cancerTypes: ['Solid tumors with on-target toxicity concerns'], developmentStage: 'phase_2', keyTrials: ['Praluzatamab ravtansine'], advantages: ['Reduced systemic toxicity', 'Improved therapeutic window', 'Better tolerated'], challenges: ['Protease specificity', 'Heterogeneous activation'], estimatedTimeline: '2-4 years', companies: ['CytomX', 'Amgen'], references: ['ASCO/AACR presentations'] }, { id: 'ab-bicycle', name: 'Bicycle Peptides (Constrained Peptides)', category: 'antibody', mechanism: 'Small bicyclic peptides with antibody-like binding', targets: ['Nectin-4', 'EphA2', 'MT1-MMP', 'CD137'], cancerTypes: ['Solid tumors', 'Enhanced tissue penetration needed'], developmentStage: 'phase_2', keyTrials: ['BT5528', 'BT8009'], advantages: ['Small size - rapid tumor penetration', 'Short half-life (less toxicity)', 'Multi-specific potential'], challenges: ['Short half-life (frequent dosing)', 'Manufacturing scale'], estimatedTimeline: '3-5 years', companies: ['Bicycle Therapeutics'], references: ['ASCO 2023 data'] }, { id: 'ab-nanobody', name: 'Nanobodies/VHH Antibodies', category: 'antibody', mechanism: 'Single-domain camelid antibodies with enhanced properties', targets: ['Various - modular platform'], cancerTypes: ['Solid tumors', 'CNS tumors', 'Theranostics'], developmentStage: 'phase_2', keyTrials: ['Ciltacabtagene (BCMA nanobody CAR)'], advantages: ['Small size', 'Stability', 'Tissue penetration', 'Multispecific easy'], challenges: ['Immunogenicity potential', 'Short half-life'], estimatedTimeline: '2-4 years', companies: ['Ablynx/Sanofi', 'Multiple'], references: ['Carvykti approval'] }, { id: 'ab-conditionally-active', name: 'Conditionally Active Biologics', category: 'antibody', mechanism: 'pH-sensitive or TME-activated antibodies', targets: ['Various - platform technology'], cancerTypes: ['Solid tumors'], developmentStage: 'phase_1', keyTrials: ['Emerging'], advantages: ['Reduced systemic toxicity', 'TME-specific activation'], challenges: ['Conditional activation reliability'], estimatedTimeline: '4-6 years', companies: ['Bioatla', 'Others'], references: ['Platform publications'] }, { id: 'ab-multispecific-io', name: 'Multispecific IO Antibodies', category: 'antibody', mechanism: 'Target multiple immune checkpoints simultaneously', targets: ['PD-1xLAG3', 'PD-1xTIM3', 'PD-1xTIGIT', 'CTLA-4xPD-L1'], cancerTypes: ['ICI-resistant tumors', 'Cold tumors'], developmentStage: 'phase_2', keyTrials: ['Multiple'], advantages: ['Single molecule dual checkpoint', 'Enhanced efficacy potential'], challenges: ['Toxicity management', 'Optimal combinations unclear'], estimatedTimeline: '2-4 years', companies: ['Regeneron', 'Roche', 'Multiple'], references: ['Clinical trial data'] }, ]; // ═══════════════════════════════════════════════════════════════════════════════ // NUCLEIC ACID THERAPEUTICS (mRNA, siRNA, ASO, CRISPR) // ═══════════════════════════════════════════════════════════════════════════════ private nucleicAcidTherapies: EmergingTherapy[] = [ { id: 'na-mrna-vaccine', name: 'Personalized mRNA Neoantigen Vaccines', category: 'nucleic_acid', mechanism: 'Patient-specific neoantigen mRNA cancer vaccine', targets: ['Personalized neoantigens (up to 34 per patient)'], cancerTypes: ['Melanoma', 'Pancreatic', 'Colorectal', 'NSCLC', 'Head and Neck'], developmentStage: 'phase_2', keyTrials: ['KEYNOTE-942 (mRNA-4157)', 'Autogene cevumeran'], advantages: ['Personalized', 'Rapid manufacturing', 'Strong T-cell responses'], challenges: ['Manufacturing turnaround time', 'Cost', 'Prediction accuracy'], estimatedTimeline: '2-3 years (melanoma adjuvant)', companies: ['Moderna', 'BioNTech', 'Genentech'], references: ['KEYNOTE-942 Nature Medicine 2023'] }, { id: 'na-mrna-car', name: 'mRNA-Encoded CAR-T', category: 'nucleic_acid', mechanism: 'LNP-delivered mRNA for in vivo CAR expression', targets: ['CD19', 'Others'], cancerTypes: ['B-cell malignancies'], developmentStage: 'phase_1', keyTrials: ['Emerging'], advantages: ['No viral vectors', 'Transient expression (safety)', 'Repeat dosing'], challenges: ['Transient expression (efficacy)', 'LNP delivery optimization'], estimatedTimeline: '4-6 years', companies: ['Capstan', 'Carisma'], references: ['Preclinical data'] }, { id: 'na-sirna-oncology', name: 'siRNA Therapeutics for Cancer', category: 'nucleic_acid', mechanism: 'RNA interference to silence oncogenes', targets: ['KRAS', 'MYC', 'PD-L1', 'STAT3'], cancerTypes: ['Various solid tumors'], developmentStage: 'phase_1', keyTrials: ['DCR-MYC', 'siG12D-LODER'], advantages: ['Target "undruggable" proteins', 'Potent knockdown'], challenges: ['Delivery to tumors', 'Endosomal escape', 'Durability'], estimatedTimeline: '5-7 years', companies: ['Arrowhead', 'Alnylam', 'Dicerna'], references: ['Ongoing development'] }, { id: 'na-aso-splice', name: 'Splice-Switching ASOs for Cancer', category: 'nucleic_acid', mechanism: 'Alter splicing of oncogenic or therapeutic targets', targets: ['BCL-X (shift to pro-apoptotic)', 'MDM4', 'STAT3'], cancerTypes: ['Solid tumors', 'Hematologic malignancies'], developmentStage: 'phase_1', keyTrials: ['Limited oncology ASOs'], advantages: ['Precise splice modulation', 'Target non-coding regions'], challenges: ['Tumor delivery', 'Off-target splicing'], estimatedTimeline: '5-8 years', companies: ['Ionis', 'Stoke Therapeutics'], references: ['Preclinical publications'] }, { id: 'na-crispr-knockout', name: 'CRISPR-Edited Cell Therapies', category: 'gene_therapy', mechanism: 'CRISPR knockout of checkpoints/TCR in T-cells', targets: ['TRAC', 'PD-1', 'TIM-3', 'LAG-3', 'Beta-2-microglobulin'], cancerTypes: ['Various - platform for cell therapy'], developmentStage: 'phase_1', keyTrials: ['CRISPR-edited CAR-T trials'], advantages: ['Multi-edit capability', 'Precise editing', 'Enhanced CAR-T function'], challenges: ['Off-target editing', 'Regulatory scrutiny'], estimatedTimeline: '3-5 years', companies: ['CRISPR Therapeutics', 'Intellia', 'Caribou'], references: ['CTX110 data'] }, { id: 'na-crispr-screen', name: 'CRISPR Screening-Derived Targets', category: 'gene_therapy', mechanism: 'Identify new targets through CRISPR screens', targets: ['Novel synthetic lethalities', 'Immune evasion mechanisms'], cancerTypes: ['Target discovery platform'], developmentStage: 'preclinical', keyTrials: ['Drug development stage'], advantages: ['Unbiased discovery', 'Novel target identification'], challenges: ['Translation to therapeutics', 'Validation'], estimatedTimeline: '5-10 years to drugs', companies: ['KSQ', 'Maze', 'Multiple academic'], references: ['Nature publications'] }, { id: 'na-base-editing', name: 'Base Editing Therapeutics', category: 'gene_therapy', mechanism: 'Precise single nucleotide changes without DSBs', targets: ['Oncogenic mutations', 'Regulatory sequences'], cancerTypes: ['Potentially any with targetable mutations'], developmentStage: 'preclinical', keyTrials: ['Emerging'], advantages: ['Precise editing', 'No double-strand breaks', 'Lower off-target'], challenges: ['Delivery', 'Bystander editing'], estimatedTimeline: '5-8 years', companies: ['Beam Therapeutics', 'Verve'], references: ['Technology papers'] }, ]; // ═══════════════════════════════════════════════════════════════════════════════ // NOVEL DRUG TARGETS (PREVIOUSLY UNDRUGGABLE) // ═══════════════════════════════════════════════════════════════════════════════ private novelTargets: NovelTarget[] = [ { gene: 'MYC', protein: 'c-MYC Transcription Factor', pathway: 'Transcription', targetType: 'oncogene', druggability: 'undruggable_becoming_druggable', cancerTypes: ['Burkitt lymphoma', 'SCLC', 'Neuroblastoma', 'Many solid tumors'], approachesInDevelopment: ['MYC-MAX disruption', 'PROTAC degradation', 'siRNA', 'Aurora A inhibition (destabilize)', 'GSPT1 degraders'], leadCompounds: [ { name: 'MRT-2359', stage: 'Phase I', company: 'Monte Rosa' }, { name: 'EN-4', stage: 'Preclinical', company: 'Encode Biosciences' } ], rationale: 'MYC drives 70%+ of cancers but lacks druggable pockets - indirect approaches emerging', references: ['Nature Reviews Cancer 2023'] }, { gene: 'TP53', protein: 'p53 Tumor Suppressor', pathway: 'Cell cycle/Apoptosis', targetType: 'tumor_suppressor', druggability: 'undruggable_becoming_druggable', cancerTypes: ['>50% of all cancers have p53 alterations'], approachesInDevelopment: ['MDM2 inhibitors (restore WT)', 'p53 reactivators (mutant)', 'Gene therapy', 'Synthetic lethality'], leadCompounds: [ { name: 'Milademetan', stage: 'Phase II', company: 'RainOncology' }, { name: 'PC14586 (rezatapopt)', stage: 'Phase II', company: 'PMV Pharma' }, { name: 'APR-246', stage: 'Phase III', company: 'Aprea' } ], rationale: 'Mutant p53 reactivation and synthetic lethality approaches gaining traction', references: ['Cancer Discovery 2023'] }, { gene: 'RAS (pan)', protein: 'All RAS Isoforms', pathway: 'RAS/MAPK', targetType: 'oncogene', druggability: 'undruggable_becoming_druggable', cancerTypes: ['Pancreatic', 'Colorectal', 'NSCLC', 'Melanoma'], approachesInDevelopment: ['Mutation-specific (G12C done, G12D, G12V emerging)', 'Pan-RAS', 'RAS degraders', 'SOS1', 'SHP2'], leadCompounds: [ { name: 'MRTX1133 (G12D)', stage: 'Phase I/II', company: 'Mirati' }, { name: 'RMC-6236 (pan-RAS)', stage: 'Phase I', company: 'Revolution Medicines' }, { name: 'RMC-6291 (G12C degrader)', stage: 'Phase I', company: 'Revolution Medicines' } ], rationale: 'KRAS G12C breakthrough opened the door - now expanding to all RAS', references: ['NEJM 2023 RAS inhibitors'] }, { gene: 'ARID1A', protein: 'AT-Rich Interaction Domain 1A', pathway: 'SWI/SNF Chromatin Remodeling', targetType: 'synthetic_lethality', druggability: 'medium', cancerTypes: ['Ovarian clear cell', 'Endometrial', 'Gastric', 'Cholangiocarcinoma'], approachesInDevelopment: ['EZH2 inhibition (synthetic lethal)', 'HDAC inhibition', 'ATR inhibition', 'ARID1B targeting'], leadCompounds: [ { name: 'Tazemetostat', stage: 'Approved (EZH2)', company: 'Epizyme' }, { name: 'Novel ARID1B inhibitors', stage: 'Preclinical', company: 'Multiple' } ], rationale: 'ARID1A loss creates dependencies that can be therapeutically exploited', references: ['Nature Medicine synthetic lethality'] }, { gene: 'SMARCA4', protein: 'BRG1 (SWI/SNF ATPase)', pathway: 'SWI/SNF Chromatin Remodeling', targetType: 'synthetic_lethality', druggability: 'medium', cancerTypes: ['NSCLC', 'Ovarian (SCCOHT)', 'Thoracic SMARCA4-deficient tumors'], approachesInDevelopment: ['CDK4/6 inhibition', 'SMARCA2 inhibition', 'Aurora A inhibition', 'EZH2 inhibition'], leadCompounds: [ { name: 'SMARCA2 degraders', stage: 'Phase I', company: 'Foghorn' }, { name: 'FHD-286', stage: 'Phase I', company: 'Foghorn Therapeutics' } ], rationale: 'SMARCA4 loss creates dependency on SMARCA2 paralog', references: ['Nature 2023 SMARCA4'] }, { gene: 'MTAP', protein: 'Methylthioadenosine Phosphorylase', pathway: 'Methionine Salvage', targetType: 'synthetic_lethality', druggability: 'high', cancerTypes: ['Pancreatic', 'GBM', 'Mesothelioma', 'NSCLC (15% deleted)'], approachesInDevelopment: ['MAT2A inhibition', 'PRMT5 inhibition', 'Dual MAT2A/PRMT5'], leadCompounds: [ { name: 'IDE397 (MAT2A)', stage: 'Phase II', company: 'IDEAYA' }, { name: 'AMG 193 (PRMT5)', stage: 'Phase I', company: 'Amgen' }, { name: 'TNG908 (PRMT5)', stage: 'Phase I', company: 'Tango' } ], rationale: 'MTAP co-deletion with CDKN2A creates metabolic vulnerability', references: ['AACR 2023 MTAP'] }, { gene: 'WRN', protein: 'Werner Syndrome RecQ Like Helicase', pathway: 'DNA Repair', targetType: 'synthetic_lethality', druggability: 'high', cancerTypes: ['MSI-H/dMMR cancers (colorectal, endometrial, gastric)'], approachesInDevelopment: ['WRN helicase inhibitors', 'WRN degraders'], leadCompounds: [ { name: 'HRO761', stage: 'Phase I', company: 'Novartis' }, { name: 'VVD-133214', stage: 'Phase I', company: 'Vividion' } ], rationale: 'MSI-H tumors depend on WRN - synthetic lethal opportunity', references: ['Nature Cancer 2022'] }, { gene: 'USP1', protein: 'Ubiquitin-Specific Protease 1', pathway: 'DNA Repair/Fanconi Anemia', targetType: 'synthetic_lethality', druggability: 'high', cancerTypes: ['BRCA1/2 mutant cancers', 'PARP inhibitor resistant'], approachesInDevelopment: ['USP1 inhibitors'], leadCompounds: [ { name: 'KSQ-4279', stage: 'Phase I', company: 'KSQ Therapeutics' }, { name: 'TNG348', stage: 'Phase I', company: 'Tango Therapeutics' } ], rationale: 'USP1 inhibition synthetic lethal with BRCA deficiency, overcomes PARPi resistance', references: ['Cell 2022'] }, { gene: 'POLQ', protein: 'DNA Polymerase Theta', pathway: 'DNA Repair (TMEJ)', targetType: 'synthetic_lethality', druggability: 'high', cancerTypes: ['HRD tumors', 'BRCA-mutant', 'PARP-resistant'], approachesInDevelopment: ['POLQ inhibitors', 'Combination with PARP inhibitors'], leadCompounds: [ { name: 'ART4215', stage: 'Phase I', company: 'Artios' }, { name: 'Novobiocin (repurposed)', stage: 'Phase I', company: 'Academic' } ], rationale: 'Alternative to PARP inhibition for HRD tumors', references: ['Nature Cancer 2023'] }, { gene: 'CD47', protein: 'CD47 "Don\'t Eat Me" Signal', pathway: 'Innate Immunity', targetType: 'immune', druggability: 'high', cancerTypes: ['AML', 'MDS', 'NHL', 'Solid tumors'], approachesInDevelopment: ['Anti-CD47 antibodies', 'SIRPα decoys', 'Bispecifics'], leadCompounds: [ { name: 'Magrolimab', stage: 'Phase III', company: 'Gilead' }, { name: 'Evorpacept', stage: 'Phase III', company: 'ALX Oncology' } ], rationale: 'Block macrophage checkpoint to enable phagocytosis', references: ['Blood 2023'] }, { gene: 'HPK1', protein: 'Hematopoietic Progenitor Kinase 1', pathway: 'T-cell Signaling', targetType: 'immune', druggability: 'high', cancerTypes: ['Solid tumors (IO combinations)'], approachesInDevelopment: ['Small molecule HPK1 inhibitors'], leadCompounds: [ { name: 'CFI-402411', stage: 'Phase I', company: 'Treadwell/Pfizer' } ], rationale: 'HPK1 inhibition enhances T-cell activation and anti-tumor immunity', references: ['Science Translational Medicine'] }, ]; // ═══════════════════════════════════════════════════════════════════════════════ // AI-DISCOVERED DRUGS // ═══════════════════════════════════════════════════════════════════════════════ private aiDiscoveredDrugs: AIDiscoveredDrug[] = [ { id: 'ai-dsp-1181', name: 'DSP-1181', aiPlatform: 'Exscientia', discoveryMethod: 'AI-driven design + active learning', target: 'Serotonin receptor', indication: 'OCD (first; oncology follow)', developmentStage: 'Phase I completed', company: 'Sumitomo Dainippon/Exscientia', timeFromDiscoveryToClinic: '12 months (vs typical 4-5 years)', novelty: 'First AI-designed drug to enter clinical trials' }, { id: 'ai-insilico-isk', name: 'INS018_055', aiPlatform: 'Insilico Medicine', discoveryMethod: 'Generative AI + chemistry optimization', target: 'TNIK (Traf2 and Nck-Interacting Kinase)', indication: 'Idiopathic Pulmonary Fibrosis (oncology applications potential)', developmentStage: 'Phase II', company: 'Insilico Medicine', timeFromDiscoveryToClinic: '18 months', novelty: 'Novel target + novel molecule both AI-discovered' }, { id: 'ai-recursion-rxc', name: 'REC-994', aiPlatform: 'Recursion', discoveryMethod: 'Phenotypic screening + ML', target: 'GM-CSF signaling', indication: 'CCM (Cerebral Cavernous Malformations)', developmentStage: 'Phase II/III', company: 'Recursion Pharmaceuticals', timeFromDiscoveryToClinic: 'Repurposed - accelerated', novelty: 'AI-enabled drug repurposing' }, { id: 'ai-isomorphic', name: 'Isomorphic Labs Compounds', aiPlatform: 'AlphaFold/DeepMind', discoveryMethod: 'Structure prediction + drug design', target: 'Multiple', indication: 'Eli Lilly and Novartis partnerships', developmentStage: 'Preclinical/Early Phase', company: 'Isomorphic Labs/Lilly/Novartis', timeFromDiscoveryToClinic: 'In progress', novelty: 'DeepMind-powered structure-based drug design' }, { id: 'ai-absci', name: 'Absci Biologic Designs', aiPlatform: 'Absci Integrated Drug Creation', discoveryMethod: 'Generative AI for antibody design', target: 'Multiple biologic targets', indication: 'Various', developmentStage: 'Preclinical', company: 'Absci/Partners', timeFromDiscoveryToClinic: 'De novo antibody in 6 weeks', novelty: 'Zero-shot generative antibody design' }, { id: 'ai-xaira', name: 'Xaira Therapeutics Pipeline', aiPlatform: 'Multiple AI platforms', discoveryMethod: 'Lab-in-the-loop AI drug discovery', target: 'Undisclosed', indication: 'Oncology and beyond', developmentStage: 'Discovery/Preclinical', company: 'Xaira Therapeutics', timeFromDiscoveryToClinic: 'Building pipeline', novelty: '$1B+ AI drug discovery company (2024)' }, { id: 'ai-tempus', name: 'Tempus AI-Matched Trials', aiPlatform: 'Tempus', discoveryMethod: 'AI matching patients to trials and treatments', target: 'N/A - Platform', indication: 'Precision matching across cancers', developmentStage: 'Clinical implementation', company: 'Tempus', timeFromDiscoveryToClinic: 'Real-time matching', novelty: 'AI-driven clinical decision support and trial matching' }, ]; // ═══════════════════════════════════════════════════════════════════════════════ // PUBLIC API METHODS // ═══════════════════════════════════════════════════════════════════════════════ async getNextGenCellularTherapies(type?: string): Promise { let therapies = this.nextGenCellular; if (type) { therapies = therapies.filter(t => t.type === type); } return therapies; } async getProteinDegraders(targetType?: string): Promise { let degraders = this.proteinDegraders; if (targetType) { degraders = degraders.filter(d => d.type === targetType); } return degraders; } async getRadiopharmaceuticals(emissionType?: string): Promise { let therapies = this.radiopharmaceuticals; if (emissionType) { therapies = therapies.filter(t => t.emissionType === emissionType); } return therapies; } async getNovelAntibodyTech(): Promise { return this.novelAntibodyTech; } async getNucleicAcidTherapies(): Promise { return this.nucleicAcidTherapies; } async getNovelTargets(druggability?: string): Promise { let targets = this.novelTargets; if (druggability) { targets = targets.filter(t => t.druggability === druggability); } return targets; } async getAIDiscoveredDrugs(): Promise { return this.aiDiscoveredDrugs; } async getAllEmergingTherapies(): Promise<{ cellularTherapies: NextGenCellularTherapy[]; proteinDegraders: ProteinDegrader[]; radiopharmaceuticals: RadiopharmaceuticalTherapy[]; novelAntibodies: EmergingTherapy[]; nucleicAcidTherapies: EmergingTherapy[]; novelTargets: NovelTarget[]; aiDiscoveredDrugs: AIDiscoveredDrug[]; }> { return { cellularTherapies: this.nextGenCellular, proteinDegraders: this.proteinDegraders, radiopharmaceuticals: this.radiopharmaceuticals, novelAntibodies: this.novelAntibodyTech, nucleicAcidTherapies: this.nucleicAcidTherapies, novelTargets: this.novelTargets, aiDiscoveredDrugs: this.aiDiscoveredDrugs }; } async searchEmergingTherapiesForCancer(cancerType: string): Promise<{ cellular: NextGenCellularTherapy[]; degraders: ProteinDegrader[]; radiopharmaceuticals: RadiopharmaceuticalTherapy[]; antibodies: EmergingTherapy[]; nucleicAcid: EmergingTherapy[]; targets: NovelTarget[]; }> { const lowerCancer = cancerType.toLowerCase(); return { cellular: this.nextGenCellular.filter(t => t.cancerTypes.some(c => c.toLowerCase().includes(lowerCancer)) ), degraders: this.proteinDegraders.filter(d => d.cancerTypes.some(c => c.toLowerCase().includes(lowerCancer)) ), radiopharmaceuticals: this.radiopharmaceuticals.filter(r => r.cancerTypes.some(c => c.toLowerCase().includes(lowerCancer)) ), antibodies: this.novelAntibodyTech.filter(a => a.cancerTypes.some(c => c.toLowerCase().includes(lowerCancer)) ), nucleicAcid: this.nucleicAcidTherapies.filter(n => n.cancerTypes.some(c => c.toLowerCase().includes(lowerCancer)) ), targets: this.novelTargets.filter(t => t.cancerTypes.some(c => c.toLowerCase().includes(lowerCancer)) ) }; } getStatistics(): { totalCellularTherapies: number; totalProteinDegraders: number; totalRadiopharmaceuticals: number; totalNovelAntibodies: number; totalNucleicAcid: number; totalNovelTargets: number; totalAIDrugs: number; breakdownByStage: Record; } { const allTherapies = [ ...this.novelAntibodyTech, ...this.nucleicAcidTherapies ]; const stageBreakdown: Record = {}; allTherapies.forEach(t => { stageBreakdown[t.developmentStage] = (stageBreakdown[t.developmentStage] || 0) + 1; }); return { totalCellularTherapies: this.nextGenCellular.length, totalProteinDegraders: this.proteinDegraders.length, totalRadiopharmaceuticals: this.radiopharmaceuticals.length, totalNovelAntibodies: this.novelAntibodyTech.length, totalNucleicAcid: this.nucleicAcidTherapies.length, totalNovelTargets: this.novelTargets.length, totalAIDrugs: this.aiDiscoveredDrugs.length, breakdownByStage: stageBreakdown }; } }